Welcome to our dedicated page for NeuroPace SEC filings (Ticker: NPCE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroPace, Inc. SEC filings document the company's medical-device business, Nasdaq-listed common stock and public-company reporting obligations for the RNS System epilepsy therapy. Form 8-K reports cover operating results, financial condition, corporate updates, material agreements, clinical or regulatory disclosures, and executive or compensation-related events.
Proxy filings describe NeuroPace governance matters, including annual meeting proposals, director elections, auditor ratification and stockholder voting mechanics. The filing record also provides formal disclosure on capital structure, officer transitions, separation or consulting arrangements, and risk areas associated with commercialization, clinical evidence and regulatory oversight of neurostimulation devices.
NeuroPace, Inc. reported the results of its 2026 Annual Meeting of Stockholders held by live webcast on June 5, 2026. Stockholders elected Class II directors Lisa Andrade and Scott Huennekens to serve until the 2029 annual meeting and until their successors are elected and qualified.
Andrade received 15,194,450 votes for and 6,024,133 withheld, with 8,048,133 broker non-votes. Huennekens received 20,973,382 votes for and 245,201 withheld, with the same 8,048,133 broker non-votes. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,850,105 votes for, 209,301 against, and 207,310 abstentions.
NeuroPace Inc director R Scott Huennekens received new equity awards as compensation. He was granted 2,890 shares of Common Stock and a stock option for 5,368 shares at an exercise price of $15.74 per share.
The 2,890 shares will vest in twelve equal monthly installments, and the 5,368 option shares will also vest in twelve equal monthly installments, in each case conditioned on his continuous service through each vesting date. Following these awards, he holds 2,890 Common shares and 5,368 option shares directly.
NeuroPace Inc director Frank M. Fischer received equity compensation consisting of common stock and stock options. He was granted 2,890 shares of common stock at no cost, increasing his direct holdings to 598,067 shares. He was also granted options for 5,368 shares at an exercise price of $15.74 per share, expiring on June 4, 2036.
Both the shares and options vest in twelve equal monthly installments, contingent on his continuous service, which makes this a scheduled, compensation-related award rather than a market purchase or sale.
NeuroPace Inc director Uri Geiger reported new equity awards and updated holdings. He received a grant of 2,890 shares of common stock at no cost, bringing his directly held common shares to 17,748. These shares vest in twelve equal monthly installments, subject to his continuous service.
Geiger was also granted stock options for 5,368 shares of common stock at an exercise price of $15.74 per share, expiring in 2036, which likewise vest in twelve equal monthly installments while he remains in service. Separately, 4,432,948 common shares are held indirectly through Accelmed Partners II LP, an entity over which he has sole voting and dispositive power.
NeuroPace Inc director Rakhi Kumar received new equity awards. On the reported date, Kumar was granted 2,890 shares of common stock at no purchase price, increasing direct holdings to 22,050 shares.
Kumar was also granted stock options for 5,368 shares of common stock at an exercise price of $15.74, expiring in 2036. Both the stock and option grants vest in twelve equal monthly installments, contingent on continued service through each vesting date.
NeuroPace Inc director Renee Ryan received new equity awards as part of compensation. She was granted 2,890 shares of common stock at no cost, bringing her direct common stock holdings to 2,890 shares after the transaction.
She also received stock options for 5,368 shares of common stock at an exercise price of $15.74 per share, with 5,368 options held after the grant. Both the share grant and the options vest in twelve equal consecutive monthly installments, conditioned on her continuous service through each vesting date, and the options expire on June 4, 2036.
NeuroPace Inc director Lisa Andrade received new equity compensation consisting of common shares and stock options. She was granted 2,890 shares of Common Stock at no cost, all held directly. Following this grant, she directly owns 2,890 common shares.
She was also granted a Stock Option for 5,368 shares of Common Stock at an exercise price of $15.74 per share, expiring on June 4, 2036. Both the shares and the option vest in twelve equal monthly installments, contingent on her continuous service through each vesting date.
NeuroPace Inc director and CEO Joel Becker reported a routine share disposition tied to equity compensation. On June 3, 2026, 1,255 shares of common stock were withheld by the company at $15.88 per share to cover tax obligations from a restricted stock unit vesting. After this tax-withholding event, Becker directly holds 140,436 shares of NeuroPace common stock.
NeuroPace Inc director and CEO Joel Becker had 1,126 shares of Common Stock withheld on May 27, 2026 to cover taxes from a restricted stock unit vesting. This was a tax-withholding disposition by the company rather than an open-market sale.
Following the withholding, Becker directly holds 141,691 shares of NeuroPace Common Stock. The transaction reflects routine tax treatment of equity compensation and does not represent a discretionary buy or sell decision in the market.
NeuroPace Inc chief medical officer Martha Morrell reported a routine tax-withholding transaction related to equity compensation. On May 27, 2026, 358 shares of common stock were withheld by the company to cover tax obligations triggered by the vesting of a restricted stock unit award. This was not an open-market sale. After this withholding, she directly held 52,385 shares of NeuroPace common stock.